Swine

Ceva is a key partner of the swine sector, thanks to a broad range of veterinary products providing the right responses to the sanitary and zootechnical objectives of modern swine farming.

 The Group has invested heavily, especially in R&D, to offer the right products to meet the needs of professionals, notably in vaccines, reproduction and anti-infectives

  • Biological range offers safe and effective vaccines that protects swine herds from various pathologies : HYOGEN®  (Enzootic pneumonia), CIRCOVAC® (PCV2), COGLAPIX® (swine pleuropneumonia), COGLAPEST® (classical swine fever), AUPHYL Plus® (Aujeszky’s disease), PROGRESSIS® (PRRS) and PARVOJECT® (parvovirus)
  • The pharmaceutical range offers effective solutions with various strong brands led by the reproduction ultimate answer to heat synchronization - ALTRESYN®, (Altrenogest). 

With the launch of its latest innovation in its portfolio, FORCERIS® , an injectable product that treats swine neonatal coccidiosis and iron deficiency anemia in piglets. Ceva has established itself as the leading company in the iron and coccidiostats segment. The range also includes CEVAZURIL® (toltrazuril) against coccidiosis.              

Ceva's anti-infectives are  VETRIMOXIN®LA, (amoxicillin-based) and TENALINE® LA, (oxytetracycline-based). These differentiated parenteral anti-microbials have fast syringeability, easy re-suspendable formulations contained in innovative, practical, shock resistant, light and ergonomic CLAS vials. 

The pharmaceutical line up includes premixes PRACETAM® (paracetamol), and antibiotics TIAMVET® (tiamulin hydrogen fumarate), MICLOZAN® (tilmicosin phosphate) and VETRIMOXIN®50 MATRIX (granulated amoxicillin).

          

------------------------------------------

From one country to another, product lines are adapted to local demand and regulatory requirements. For further information, please take a look at the Ceva Santé Animale site for your country. Warning: the information provided on the products depends on national registrations. Access to technical information is restricted to authorised persons.

Last update: 23/10/2020

Back to top